A NEW CLASS OF MEDICINES

Meet the Challenge Accepters

It’s not every day that a groundbreaking scientific discovery leads to a potential new class of medicines. But that’s exactly what’s happening at Alnylam. From the "Eureka!" moment of discovering RNA interference (RNAi) to the clinical progress and the potential patient impact of the development of RNAi therapeutics, this 15-year journey involved the passion and persistence of countless people—people who accepted the challenge and fought for the potential of RNAi every step of the way.

You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals.

Links to all outside sites are provided as a reference for our visitors.

Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site